Strides Arcolab is currently trading at Rs. 786.50, up by 1.25 points or 0.16% from its previous closing of Rs. 785.25 on the BSE.
The scrip opened at Rs. 788.95 and has touched a high and low of Rs. 790.00 and Rs. 774.05 respectively. So far 60964 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 794.00 on 18-Jul-2012 and a 52 week low of Rs. 276.25 on 22-Aug-2011.
Last one week high and low of the scrip stood at Rs. 794.00 and Rs. 755.00 respectively. The current market cap of the company is Rs. 4611.49 crore.
The promoters holding in the company stood at 28.35% while Institutions and Non-Institutions held 55.55% and 16.11% respectively.
Strides Arcolab (Strides) has received 2 ANDA approvals from USFDA for Fluorouracil Injection USP, 50 mg/ ml, packaged in 10 ml and 20ml single- dose vials, 2.5 g / 50 ml and 5 g/100 ml pharmacy bulk packages.
Fluorouracil is amongst the product in the drugs shortage list of USFDA. According to IMS data the US market for generic fluorouracil is approximately USD 14 million. Fluorouracil is part of the oncology portfolio licensed to Pfizer for US market and expected to be launched shortly.
Fluorouracil belongs to the class of chemotherapy drugs known as anti - metabolites it interferes with the cells making DNA and RNA, which stops the growth of cancer cells and is used to treat several type of caner including colon, rectum and head and neck cancers
Strides Arcolab is a global pharmaceuticals headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceuticals products with an emphasis on sterile injectables.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: